<p>Orchestra BioMed Holdings, Inc.（NASDAQ:OBIO - 獲取免費報告）獲得了目前覆蓋該公司的八位分析師的共識推薦為 “適度買入”，MarketBeat 報告稱。一位研究分析師對該股票給予了賣出推薦，一位給予了持有推薦，五位給予了買入推薦，還有一位給予了強烈買入推薦。在過去一年中，對該股票發佈評級的經紀公司平均 12 個月的目標價格為 13.60 美元。</p>
<p>獲取 <strong>Orchestra BioMed</strong> 警報：</p>
<p>一些研究公司最近對 OBIO 發表了評論。巴克萊將 Orchestra BioMed 的目標價格從 12.00 美元下調至 11.00 美元，並在 11 月 12 日的研究報告中對該公司給予了 “增持” 評級。Cowen 於 12 月 10 日的報告中開始覆蓋 Orchestra BioMed 的股票，並給予該公司 “買入” 評級。TD Cowen 於 12 月 10 日的研究報告中開始覆蓋 Orchestra BioMed 的股票，給予了 “買入” 評級和 15.00 美元的目標價格。Chardan Capital 在 11 月 13 日的報告中重申了 “買入” 評級，並對 Orchestra BioMed 的股票設定了 20.00 美元的目標價格。最後，Weiss Ratings 在 10 月 8 日的研究報告中重新發布了對 Orchestra BioMed 股票的 “賣出（e+）” 評級。</p>
<p><strong>獲取我們最新的 Orchestra BioMed 研究報告</strong></p>
<h2>Orchestra BioMed 的機構交易</h2>
<p>機構投資者最近對該公司的持倉進行了調整。Alyeska Investment Group L.P. 在第三季度收購了價值 3,386,000 美元的 Orchestra BioMed 新頭寸。Pathstone Holdings LLC 在第三季度購買了價值 2,495,000 美元的 Orchestra BioMed 新股份。先鋒集團（Vanguard Group Inc.）在第三季度將其在 Orchestra BioMed 的持倉提高了 28.0%。先鋒集團目前擁有 1,481,875 股該公司股票，價值 3,675,000 美元，此前在上個季度又購買了 324,558 股。AMH Equity Ltd 在第三季度購買了價值約 412,000 美元的 Orchestra BioMed 新頭寸。最後，Knott David M Jr 在第二季度購買了價值約 268,000 美元的 Orchestra BioMed 新頭寸。53.20% 的股票由機構投資者和對沖基金持有。</p>
<h2>Orchestra BioMed 股票上漲 3.9%</h2>
<p>Orchestra BioMed 股票在週五開盤價為 4.31 美元。該公司的 50 日簡單移動平均為 4.35 美元，200 日簡單移動平均為 3.39 美元。公司的債務與股本比率為 0.32，速動比率為 4.72，流動比率為 4.73。Orchestra BioMed 的 52 周低點為 2.20 美元，52 周高點為 6.16 美元。該公司的市值為 2.4339 億美元，市盈率為-2.37，貝塔值為 0.63。</p>
<p>Orchestra BioMed（NASDAQ:OBIO - 獲取免費報告）最後一次發佈財報是在 11 月 10 日，報告顯示該公司季度每股收益為（0.40）美元，低於分析師共識預期的（0.38）美元，差額為（0.02）美元。該公司季度收入為 86 萬美元，而分析師預期為 74 萬美元。Orchestra BioMed 的淨利潤率為-2,665.05%，股本回報率為-320.09%。作為一個整體，股票分析師預測 Orchestra BioMed 在當前財政年度的每股收益將為-1.66。</p>
<h2>Orchestra BioMed 公司簡介</h2>
<p>（獲取免費報告）</p>
<p>Orchestra BioMed, Inc NASDAQ: OBIO 是一家臨牀階段的生物製藥公司，致力於開發針對炎症、纖維化和腫瘤疾病的靶向療法。該公司的研究專注於新型小分子項目，旨在通過利用專有的前藥和靶向抑制劑平台來解決高未滿足需求的疾病。Orchestra BioMed 的產品線包括主要候選藥物 OBI-3424，這是一種由 AKR1C3 激活的前藥，用於治療特定的實體腫瘤，以及旨在抑制病理性炎症和纖維化的下一代調節劑。</p>
<p>Orchestra BioMed 在北美進行早期和中期臨牀研究，與關鍵意見領袖和學術中心密切合作，以推進其項目。</p>
<h2>特色文章</h2>
<ul>
<li>五隻我們更看好的股票，而不是 Orchestra BioMed</li>
<li>請勿刪除，立即閲讀</li>
<li>沒有人告訴你的 100 萬億美元的人工智能故事</li>
<li>如果你在美國銀行賬户中存現金……請立即閲讀</li>
<li>在 2026 年 5 月 20 日之前購買這隻 2 美元的黃金股票</li>
<li>3 個被忽視的扣除項，幫助潛在減少資本利得税</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw"/></p>
<p><em>此即時新聞警報由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資 1000 美元在 Orchestra BioMed 嗎？</h2>
<p>在你考慮 Orchestra BioMed 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Orchestra BioMed 並不在名單上。</p>
<p>雖然 Orchestra BioMed 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

OBIO

<p>Orchestra BioMed Holdings, Inc.（納斯達克代碼：OBIO）獲得了八位分析師的 “適度買入” 共識推薦。平均十二個月的目標價格為 13.60 美元。最近的評級包括一位分析師的賣出評級、一位分析師的持有評級、五個買入評級和一個強烈買入評級。機構投資者持有該股票的 53.20%。股票開盤價為 4.31 美元，市值為 2.4339 億美元。該公司報告的季度每股收益為（0.40 美元），未達到預期，收入為 86 萬美元。Orchestra BioMed 專注於開發針對炎症和腫瘤疾病的治療方案</p>

<p>Orchestra BioMed Holdings, Inc. (NASDAQ:OBIO - Get Free Report) has earned a consensus recommendation of &#34;Moderate Buy&#34; from the eight analysts that are presently covering the firm, MarketBeat reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, five have given a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $13.60.</p>
<div class="lb-trans"><p>Orchestra BioMed Holdings, Inc.（NASDAQ:OBIO - 獲取免費報告）獲得了目前覆蓋該公司的八位分析師的共識推薦為 “適度買入”，MarketBeat 報告稱。一位研究分析師對該股票給予了賣出推薦，一位給予了持有推薦，五位給予了買入推薦，還有一位給予了強烈買入推薦。在過去一年中，對該股票發佈評級的經紀公司平均 12 個月的目標價格為 13.60 美元。</p>
</div><p>Get <strong>Orchestra BioMed</strong> alerts:</p>
<div class="lb-trans"><p>獲取 <strong>Orchestra BioMed</strong> 警報：</p>
</div><p>A number of research firms have recently commented on OBIO. Barclays cut their price objective on Orchestra BioMed from $12.00 to $11.00 and set an &#34;overweight&#34; rating for the company in a research report on Wednesday, November 12th. Cowen began coverage on shares of Orchestra BioMed in a report on Wednesday, December 10th. They issued a &#34;buy&#34; rating for the company. TD Cowen began coverage on shares of Orchestra BioMed in a research report on Wednesday, December 10th. They set a &#34;buy&#34; rating and a $15.00 price objective for the company. Chardan Capital reaffirmed a &#34;buy&#34; rating and set a $20.00 price objective on shares of Orchestra BioMed in a report on Thursday, November 13th. Finally, Weiss Ratings reissued a &#34;sell (e+)&#34; rating on shares of Orchestra BioMed in a research note on Wednesday, October 8th.</p>
<div class="lb-trans"><p>一些研究公司最近對 OBIO 發表了評論。巴克萊將 Orchestra BioMed 的目標價格從 12.00 美元下調至 11.00 美元，並在 11 月 12 日的研究報告中對該公司給予了 “增持” 評級。Cowen 於 12 月 10 日的報告中開始覆蓋 Orchestra BioMed 的股票，並給予該公司 “買入” 評級。TD Cowen 於 12 月 10 日的研究報告中開始覆蓋 Orchestra BioMed 的股票，給予了 “買入” 評級和 15.00 美元的目標價格。Chardan Capital 在 11 月 13 日的報告中重申了 “買入” 評級，並對 Orchestra BioMed 的股票設定了 20.00 美元的目標價格。最後，Weiss Ratings 在 10 月 8 日的研究報告中重新發布了對 Orchestra BioMed 股票的 “賣出（e+）” 評級。</p>
</div><p><strong>Get Our Latest Research Report on Orchestra BioMed</strong></p>
<div class="lb-trans"><p><strong>獲取我們最新的 Orchestra BioMed 研究報告</strong></p>
</div><h2>Institutional Trading of Orchestra BioMed</h2>
<div class="lb-trans"><h2>Orchestra BioMed 的機構交易</h2>
</div><p>Institutional investors have recently made changes to their positions in the company. Alyeska Investment Group L.P. acquired a new position in Orchestra BioMed in the 3rd quarter valued at $3,386,000. Pathstone Holdings LLC purchased a new stake in shares of Orchestra BioMed during the third quarter worth $2,495,000. Vanguard Group Inc. raised its position in shares of Orchestra BioMed by 28.0% in the third quarter. Vanguard Group Inc. now owns 1,481,875 shares of the company's stock valued at $3,675,000 after buying an additional 324,558 shares during the last quarter. AMH Equity Ltd purchased a new position in shares of Orchestra BioMed in the third quarter worth about $412,000. Finally, Knott David M Jr purchased a new position in shares of Orchestra BioMed in the second quarter worth about $268,000. 53.20% of the stock is owned by institutional investors and hedge funds.</p>
<div class="lb-trans"><p>機構投資者最近對該公司的持倉進行了調整。Alyeska Investment Group L.P. 在第三季度收購了價值 3,386,000 美元的 Orchestra BioMed 新頭寸。Pathstone Holdings LLC 在第三季度購買了價值 2,495,000 美元的 Orchestra BioMed 新股份。先鋒集團（Vanguard Group Inc.）在第三季度將其在 Orchestra BioMed 的持倉提高了 28.0%。先鋒集團目前擁有 1,481,875 股該公司股票，價值 3,675,000 美元，此前在上個季度又購買了 324,558 股。AMH Equity Ltd 在第三季度購買了價值約 412,000 美元的 Orchestra BioMed 新頭寸。最後，Knott David M Jr 在第二季度購買了價值約 268,000 美元的 Orchestra BioMed 新頭寸。53.20% 的股票由機構投資者和對沖基金持有。</p>
</div><h2>Orchestra BioMed Trading Up 3.9%</h2>
<div class="lb-trans"><h2>Orchestra BioMed 股票上漲 3.9%</h2>
</div><p>Shares of Orchestra BioMed stock opened at $4.31 on Friday. The firm has a 50-day simple moving average of $4.35 and a two-hundred day simple moving average of $3.39. The company has a debt-to-equity ratio of 0.32, a quick ratio of 4.72 and a current ratio of 4.73. Orchestra BioMed has a fifty-two week low of $2.20 and a fifty-two week high of $6.16. The company has a market cap of $243.39 million, a P/E ratio of -2.37 and a beta of 0.63.</p>
<div class="lb-trans"><p>Orchestra BioMed 股票在週五開盤價為 4.31 美元。該公司的 50 日簡單移動平均為 4.35 美元，200 日簡單移動平均為 3.39 美元。公司的債務與股本比率為 0.32，速動比率為 4.72，流動比率為 4.73。Orchestra BioMed 的 52 周低點為 2.20 美元，52 周高點為 6.16 美元。該公司的市值為 2.4339 億美元，市盈率為-2.37，貝塔值為 0.63。</p>
</div><p>Orchestra BioMed (NASDAQ:OBIO - Get Free Report) last posted its earnings results on Monday, November 10th. The company reported ($0.40) EPS for the quarter, missing analysts' consensus estimates of ($0.38) by ($0.02). The business had revenue of $0.86 million for the quarter, compared to analyst estimates of $0.74 million. Orchestra BioMed had a negative net margin of 2,665.05% and a negative return on equity of 320.09%. As a group, equities analysts predict that Orchestra BioMed will post -1.66 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>Orchestra BioMed（NASDAQ:OBIO - 獲取免費報告）最後一次發佈財報是在 11 月 10 日，報告顯示該公司季度每股收益為（0.40）美元，低於分析師共識預期的（0.38）美元，差額為（0.02）美元。該公司季度收入為 86 萬美元，而分析師預期為 74 萬美元。Orchestra BioMed 的淨利潤率為-2,665.05%，股本回報率為-320.09%。作為一個整體，股票分析師預測 Orchestra BioMed 在當前財政年度的每股收益將為-1.66。</p>
</div><h2>Orchestra BioMed Company Profile</h2>
<div class="lb-trans"><h2>Orchestra BioMed 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（獲取免費報告）</p>
</div><p>Orchestra BioMed, Inc NASDAQ: OBIO is a clinical‐stage biopharmaceutical company dedicated to developing targeted therapies for inflammatory, fibrotic and oncologic diseases. The company's research focuses on novel small-molecule programs designed to address high‐unmet-need conditions by leveraging proprietary prodrug and targeted inhibitor platforms. Orchestra BioMed's pipeline includes lead candidates such as OBI-3424, a prodrug activated by AKR1C3 for the treatment of select solid tumors, and next-generation modulators aimed at suppressing pathological inflammation and fibrosis.</p>
<div class="lb-trans"><p>Orchestra BioMed, Inc NASDAQ: OBIO 是一家臨牀階段的生物製藥公司，致力於開發針對炎症、纖維化和腫瘤疾病的靶向療法。該公司的研究專注於新型小分子項目，旨在通過利用專有的前藥和靶向抑制劑平台來解決高未滿足需求的疾病。Orchestra BioMed 的產品線包括主要候選藥物 OBI-3424，這是一種由 AKR1C3 激活的前藥，用於治療特定的實體腫瘤，以及旨在抑制病理性炎症和纖維化的下一代調節劑。</p>
</div><p>Orchestra BioMed conducts early‐ and mid-stage clinical studies in North America, working closely with key opinion leaders and academic centers to advance its programs.</p>
<div class="lb-trans"><p>Orchestra BioMed 在北美進行早期和中期臨牀研究，與關鍵意見領袖和學術中心密切合作，以推進其項目。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>特色文章</h2>
</div><ul>
<li>Five stocks we like better than Orchestra BioMed</li>
<li>Do not delete, read immediately</li>
<li>The $100 Trillion AI Story No One Is Telling You</li>
<li>If You Keep Cash In A U.S. Bank Account… Read This NOW</li>
<li>But this $2 Gold Stock Before May 20, 2026</li>
<li>3 Overlooked Deductions to Help Potentially Minimize Capital Gains Tax</li>
</ul>
<div class="lb-trans"><ul>
<li>五隻我們更看好的股票，而不是 Orchestra BioMed</li>
<li>請勿刪除，立即閲讀</li>
<li>沒有人告訴你的 100 萬億美元的人工智能故事</li>
<li>如果你在美國銀行賬户中存現金……請立即閲讀</li>
<li>在 2026 年 5 月 20 日之前購買這隻 2 美元的黃金股票</li>
<li>3 個被忽視的扣除項，幫助潛在減少資本利得税</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9T0JJTw" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=OBIO"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞警報由敍述科學技術和來自 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或評論發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Orchestra BioMed Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資 1000 美元在 Orchestra BioMed 嗎？</h2>
</div><p>Before you consider Orchestra BioMed, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 Orchestra BioMed 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Orchestra BioMed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其推薦給客户的股票。MarketBeat 已識別出五隻頂級分析師悄悄向客户推薦的股票，以便在更廣泛的市場注意到之前購買……而 Orchestra BioMed 並不在名單上。</p>
</div><p>While Orchestra BioMed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 Orchestra BioMed 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

Orchestra BioMed Holdings, Inc.（NASDAQ 代碼：OBIO）被分析師一致推薦為 “適度買入”